ophthalmic screening

Tamoxifen-related retinal toxicity is known but ophthalmic evaluations after initiation are infrequent. Recent data reveal low screening rates, rare retinal-specific testing, and no greater ophthalmic use than aromatase inhibitors. Emerging imaging biomarkers highlight subtle early retinal changes, underscoring the need for evidence-based screening guidelines.